-PDF Download- Oral Antidiabetic Drugs And Glp 1 Analogues In The Treatment Of Type 2 Diabetes EBOOK

Oral antidiabetic drugs and GLP-1 analogues in the treatment of type 2 diabetes

Author: Sics Editore

Publisher: SICS Editore

Published: 2014-10-01

Total Pages: 34

ISBN-13: 8869304906

Oral medication should be introduced at an early stage. In the absence of contraindications, medication should be started when the HbA1c concentration exceeds 6.5–7.0% (48–53 mmol/mol) despite non-pharmacological intervention. Metformin is the drug of choice. If one antidiabetic drug does not lower the HbA1c value to below 7.0 % (53 mmol/mol), add another and possibly a third antidiabetic drug unless there are contraindications. Insulin therapy must be initiated at the latest when HbA1c remains over 7.0% despite medication with oral antidiabetic drugs or with injectable GLP-1 analogues. A GLP-1 analogue may also be combined with basic insulin treatment.

Drug-Induced Liver Disease

Author: Neil Kaplowitz

Publisher: CRC Press

Published: 2002-10-16

Total Pages: 790

ISBN-13: 0203909127

DOWNLOAD EBOOK →

Featuring more than 4100 references, Drug-Induced Liver Disease will be an invaluable reference for gastroenterologists, hepatologists, family physicians, internists, pathologists, pharmacists, pharmacologists, and clinical toxicologists, and graduate and medical school students in these disciplines.

The American Diabetes Association/JDRF Type 1 Diabetes Sourcebook

Author: Anne L. Peters

Publisher: American Diabetes Association

Published: 2013-03-29

Total Pages: 576

ISBN-13: 1580405061

DOWNLOAD EBOOK →

The American Diabetes Association/JDRF Type 1 Diabetes Sourcebook serves as both an evidence-based reference work and consensus report outlining the most critical components of care for individuals with type 1 diabetes throughout their lifespan. The volume serves not only as a comprehensive guide for clinicians, but also reviews the evidence supporting these components of care and provides a perspective on the critical areas of research that are needed to improve our understanding of type 1 diabetes diagnosis and treatment. The volume focuses specifically on the needs of patients with type 1 diabetes and provides clear and detailed guidance on the current standards for the optimal treatment of type 1 diabetes from early childhood to later life. To accomplish the book’s editorial goals, Editors-in-Chief, Drs. Anne Peters and Lori Laffel, assembled an editorial steering committee of prominent research physicians, clinicians, and educators to develop the topical coverage. In addition, a Managing Editor was brought on to help the authors write and focus their chapters.

Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment

Author: Enzo Bonora

Publisher: Springer

Published: 2018-10-23

Total Pages: 0

ISBN-13: 9783319450148

DOWNLOAD EBOOK →

This book provides the reader with comprehensive information on the epidemiology, etiology, pathogenesis, pathophysiology, clinical features, prevention, and treatment of diabetes with the aim of empowering health care providers in their daily battle against the disease. Diabetes has been identified by WHO and the United Nations as a medical emergency because of the increase in its global prevalence, which may reach one billion in three to four decades if the trend remains unchanged. Despite improved care that is helping to prolong life, diabetes impacts substantially on the quality of life of those affected and kills or disables several million people each year. The disease is systemic because all organs, tissues, and cells suffer in the presence of hyperglycemia and are damaged by the diabetic milieu. Unfortunately, most patients with diabetes will consequently experience chronic diabetic complications. This book, combining basic science with a practical clinical orientation, will be of value for all physicians and nurses who care for patients with diabetes.

Hypoglycemia in Diabetes

Author: Philip Cryer

Publisher: American Diabetes Association

Published: 2016-07-12

Total Pages: 194

ISBN-13: 1580406491

DOWNLOAD EBOOK →

Intended for diabetes researchers and medical professionals who work closely with patients with diabetes, this newly updated and expanded edition provides new perspectives and direct insight into the causes and consequences of this serious medical condition from one of the foremost experts in the field. Using the latest scientific and medical developments and trends, readers will learn how to identify, prevent, and treat this challenging phenomenon within the parameters of the diabetes care regimen.

Drug Therapy for Type 2 Diabetes

Author: Andrew Krentz

Publisher: Springer Science & Business Media

Published: 2013-08-13

Total Pages: 107

ISBN-13: 1908517778

DOWNLOAD EBOOK →

This Adis Pocket Reference presents an up-to-date, succinct, and practical approach to drug therapy for type 2 diabetes.

WHO Best Practices for Injections and Related Procedures Toolkit

Author:

Publisher:

Published: 2010

Total Pages: 55

ISBN-13: 9789241599252

DOWNLOAD EBOOK →

The new WHO guidelines provide recommended steps for safe phlebotomy and reiterate accepted principles for drawing, collecting blood and transporting blood to laboratories/blood banks. The main areas covered by the toolkit are: 1. bloodborne pathogens transmitted through unsafe injection practices;2. relevant elements of standard precautions and associated barrier protection;3. best injection and related infection prevention and control practices;4. occupational risk factors and their management.

Hepatotoxicity

Author: Hyman J. Zimmerman

Publisher: Lippincott Williams & Wilkins

Published: 1999

Total Pages: 848

ISBN-13: 9780781719520

DOWNLOAD EBOOK →

Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury.

Successful Drug Discovery, Volume 5

Author: Janos Fischer

Publisher: John Wiley & Sons

Published: 2021-02-12

Total Pages: 340

ISBN-13: 3527826866

DOWNLOAD EBOOK →

Filled with unique insights into current drugs that have made it to the marketplace In the fifth volume of Successful Drug Discovery, the inventors and primary developers of drugs that made it to the market tell the story of the drugs discovery and development. Case studies of drugs from different therapeutic fields reveal the all-too-often unpredictable path from the first drug candidate molecule to the successfully marketed drug. In addition, this new volume addresses overarching topics for drug discovery, such as drug discovery in academia, and discusses currently important classes of small molecule as well as biological drugs. Comprehensive in scope, the books nine chapters provide a representative cross-section of the present-day drug development effort. The authoritative fifth volume is filled with relevant data and chemical information, as well as the insight and experience of the best contemporary drug creators. This important volume: - Puts the focus on recently introduced drugs that have not yet made it into standard textbooks or general references - Contains information and insight that is new and often not even available from the primary literature - Reveals what it takes to successfully develop a drug molecule that has made it all the way to the market - Is endorsed and supported by the International Union of Pure and Applied Chemistry (IUPAC) Written for medicinal chemists, pharmaceutical chemists, organic chemists, Successful Drug Discovery, Volume Five reveals the most recent techniques used by drug innovators in the drug development process.

New Drugs for Type 2 Diabetes

Author:

Publisher:

Published: 2017

Total Pages: 105

ISBN-13:

DOWNLOAD EBOOK →

Pharmacologic treatment of type 2 diabetes following the failure of conventional diet and exercise interventions begins with metformin (except where contraindicated). Inadequate glycemic control with metformin is common. Treatment algorithms recommend the addition of oral or injectable antidiabetic drugs or insulin to metformin as a next step (second-line therapy). Previous CADTH reports (2013) on second-line therapy provided comparative efficacy and cost-effectiveness recommendations. Since then, a new drug class has entered the Canadian market for the treatment of patients with type 2 diabetes -- sodium-glucose cotransporter-2 (SGLT-2) inhibitors. In addition, a fourth dipeptidyl peptidase-4 (DPP-4) inhibitor (alogliptin) as well as a third glucagon-like peptide-1 (GLP-1) analogue (dulaglutide) have appeared on the Canadian market, and new data on the impact on cardiovascular outcomes of some of the new drugs (e.g., GLP-1 agonists, DDP-4 inhibitors, and SGLT-2 inhibitors) have been published recently. As a result, there is a need to reassess the comparative efficacy, safety, and cost-effectiveness of the available drug classes for the treatment of patients with type 2 diabetes.